GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Medicilon Inc (SHSE:688202) » Definitions » Research & Development

Shanghai Medicilon (SHSE:688202) Research & Development : ¥119 Mil (TTM As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Shanghai Medicilon Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Shanghai Medicilon's Research & Development for the three months ended in Mar. 2024 was ¥25 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 was ¥119 Mil.

Shanghai Medicilon Research & Development Historical Data

The historical data trend for Shanghai Medicilon's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Medicilon Research & Development Chart

Shanghai Medicilon Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 28.19 46.96 77.76 122.88 122.39

Shanghai Medicilon Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.37 32.81 34.72 26.49 24.85

Shanghai Medicilon Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥119 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Medicilon  (SHSE:688202) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Shanghai Medicilon Research & Development Related Terms

Thank you for viewing the detailed overview of Shanghai Medicilon's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Medicilon (SHSE:688202) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Medicilon Inc (SHSE:688202) » Definitions » Research & Development
Comparable Companies
SZSE:000990 SHSE:600201 SHSE:688382 SHSE:688076 SHSE:688062 SHSE:605116 SHSE:600645 SZSE:300049 SZSE:300841 SHSE:688315 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
Lane 67, Libing Road, Building 5, Pilot Free Trade Zone, Shanghai, CHN, 201299
Website
http://www.medicilon.com.cn
Shanghai Medicilon Inc is a comprehensive biomedical research and developemnt service company. It provides a full range of one-stop new drug development services for pharmaceutical companies and research institutions around the world in line with domestic and international reporting standards.

Shanghai Medicilon (SHSE:688202) Headlines

No Headlines